trial

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

NCTId NCT04761861
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Sadat City University
Primary completion 2025-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2021-02-16
Primary completion
2025-12-31
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Vildagliptin 50 MG

Sponsors

Sadat City UniversityLead Sponsor

Sites

1 total
Shibīn al Kawm, Egypt

Linked catalysts

1
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia — primary completion2025-12-31

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2025-12-31
Status
WITHDRAWN
relationships
The graph out of here
drug
Vildagliptin 50 MG
drug
lead_sponsor
Sadat City University
company
indication
Schizophrenia
indication
Dyslipidemias
indication
Dyslipidemias
indication